Department of Gynecology and Obstetrics, Botucatu Medical School, São Paulo State University, Botucatu, São Paulo, Brazil.
Int J Gynecol Cancer. 2010 Dec;20(9):1525-30. doi: 10.1111/IGC.0b013e3181f7b33b.
This study was undertaken to investigate the expression of p53, Ki-67, and CD31 proteins in endometrial polyps of postmenopausal women treated with tamoxifen (TAM). Postmenopausal women with endometrial polyps treated with TAM (n = 20), postmenopausal women with endometrial polyps without hormone use (n = 20), postmenopausal women with atrophic endometrium (n = 20), and postmenopausal women with endometrial adenocarcinoma (n = 20) were prospectively investigated. Tissue samples were immunohistochemically evaluated by monoclonal antibodies for p53, Ki-67, and CD31. The data were analyzed using the Student t test, analysis of variance, and χ2 to evaluate significant differences between the groups. The level of significance was set at P < 0.05. There was no difference in the expression of p53 between the groups (P = 0.067). The expression of Ki-67 was higher in the polyp samples from TAM-treated women compared with those from the women using no hormone (P = 0.0047) and those from the women with atrophic endometrium (P = 0.008). Samples from the women with endometrial cancer was associated with higher Ki-67 expression compared with the polyp samples from TAM-treated women (P = 0.004). The expression of CD31 was higher in the polyp samples of TAM-treated women compared with that of the samples from the women with atrophic endometrium (P < 0.001) and similar to the polyp samples from the women using no hormone (P = 0.319) and to the samples from the women with endometrial cancer (P = 0.418). The use of TAM in postmenopausal women might be associated with increased cellular proliferation in endometrial polyps without interfering angiogenesis or inactivation of tumor suppressor proteins.
这项研究旨在探讨绝经后接受他莫昔芬（TAM）治疗的子宫内膜息肉患者中 p53、Ki-67 和 CD31 蛋白的表达。前瞻性研究了 20 例接受 TAM 治疗的绝经后子宫内膜息肉患者、20 例未使用激素的绝经后子宫内膜息肉患者、20 例萎缩性子宫内膜患者和 20 例子宫内膜腺癌患者。采用单克隆抗体对组织样本进行免疫组织化学评估，检测 p53、Ki-67 和 CD31。使用 Student t 检验、方差分析和 χ2 分析评估组间差异的统计学意义。显著性水平设定为 P < 0.05。各组间 p53 的表达无差异（P = 0.067）。与未使用激素和萎缩性子宫内膜患者相比，TAM 治疗患者的息肉样本中 Ki-67 的表达更高（P = 0.0047 和 P = 0.008）。与 TAM 治疗患者的息肉样本相比，子宫内膜癌患者的样本 Ki-67 表达更高（P = 0.004）。与萎缩性子宫内膜患者相比，TAM 治疗患者的息肉样本中 CD31 的表达更高（P < 0.001），与未使用激素的患者的息肉样本相似（P = 0.319），与子宫内膜癌患者的样本相似（P = 0.418）。TAM 在绝经后妇女中的使用可能与子宫内膜息肉中细胞增殖增加有关，而不会干扰血管生成或肿瘤抑制蛋白失活。
